Pub Date : 2025-02-18DOI: 10.23736/S2784-8671.25.08176-9
Luigi Coronella, Giuseppe Lauletta, Mario DE Lucia, Fabrizio Martora, Maria C Annunziata
{"title":"A study on acne perception and myths among high school students in southern Italy: insights from a four-question survey.","authors":"Luigi Coronella, Giuseppe Lauletta, Mario DE Lucia, Fabrizio Martora, Maria C Annunziata","doi":"10.23736/S2784-8671.25.08176-9","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08176-9","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143441027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-13DOI: 10.23736/S2784-8671.24.08030-7
Alba Navarro-Bielsa, Manuel Almenara-Blasco, Tamara Gracia-Cazaña, Ignacio Ros, Carmen Gomez Mateo, Pedro Gil-Pallares, Yolanda Gilaberte
{"title":"Paradoxical psoriasiform eruption in pediatric patients with inflammatory bowel disease treated with adalimumab.","authors":"Alba Navarro-Bielsa, Manuel Almenara-Blasco, Tamara Gracia-Cazaña, Ignacio Ros, Carmen Gomez Mateo, Pedro Gil-Pallares, Yolanda Gilaberte","doi":"10.23736/S2784-8671.24.08030-7","DOIUrl":"https://doi.org/10.23736/S2784-8671.24.08030-7","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-13DOI: 10.23736/S2784-8671.25.08064-8
Lisa Nunziata, Camilla Peccianti, Cesira Nencioni, Susanna Fabbroni, Barbara Rossetti, Pietro Rubegni, Michele Pellegrino
{"title":"A case of cutaneous diphtheria and migration flows.","authors":"Lisa Nunziata, Camilla Peccianti, Cesira Nencioni, Susanna Fabbroni, Barbara Rossetti, Pietro Rubegni, Michele Pellegrino","doi":"10.23736/S2784-8671.25.08064-8","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08064-8","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-13DOI: 10.23736/S2784-8671.24.07927-1
Andrea Picchianti Diamanti, Marco Galluzzo, Annunziata Dattola, Arianna D'Antonio, Augusta Ortolan, Domenico Giordano, Magda D'Agostino, Rossana Scrivo
{"title":"Treating psoriatic arthritis in the early phase: proposal for a shared dermatological and rheumatological therapeutic intervention with biologics and targets synthetic disease-modifying immunosuppressive drugs.","authors":"Andrea Picchianti Diamanti, Marco Galluzzo, Annunziata Dattola, Arianna D'Antonio, Augusta Ortolan, Domenico Giordano, Magda D'Agostino, Rossana Scrivo","doi":"10.23736/S2784-8671.24.07927-1","DOIUrl":"https://doi.org/10.23736/S2784-8671.24.07927-1","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143407810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: Atopic dermatitis (AD) stands as the prevailing chronic relapsing inflammatory dermatosis within the general population. Scalp involvement is a minor but frequent feature of AD, nevertheless it was relatively understudied up to now. This research aims to better describe the clinical and trichoscopic aspects of scalp involvement in moderate-to-severe AD, focusing on the vascular pattern of the vessels and scalp desquamation.
Methods: A single-center retrospective and prospective study was conducted on 20 patients, collecting clinical and trichoscopic images at the Dermatology Unit of the University of Bologna, Italy.
Results: Scalp lesions exhibited distinct morphological characteristics in both vascular and desquamation patterns. Three main trichoscopic patterns with a different grade of involvement were identified: erythematous pattern, erythematous desquamative pattern and exudative with crusts pattern. As for the limitations, the sample size was relatively small, and, being a single-centre study, the results may not be applicable to other populations or settings. In addition, no standardized criteria for trichoscopic analysis are available.
Conclusions: This is the first study with the purpose to delineate the trichoscopic characteristics observed in patients with moderate-to-severe AD not in systemic therapy, thereby highlighting three distinct patterns of trichoscopy manifestations that define three distinct populations.
{"title":"Trichoscopic clues of the scalp in moderate to severe atopic dermatitis: a monocentric analysis.","authors":"Michela Starace, Carlotta Gurioli, Gionathan Orioni, Stephano Cedirian, Tullio Brunetti, Luca Rapparini, Bianca M Piraccini","doi":"10.23736/S2784-8671.25.08127-7","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08127-7","url":null,"abstract":"<p><strong>Background: </strong>Atopic dermatitis (AD) stands as the prevailing chronic relapsing inflammatory dermatosis within the general population. Scalp involvement is a minor but frequent feature of AD, nevertheless it was relatively understudied up to now. This research aims to better describe the clinical and trichoscopic aspects of scalp involvement in moderate-to-severe AD, focusing on the vascular pattern of the vessels and scalp desquamation.</p><p><strong>Methods: </strong>A single-center retrospective and prospective study was conducted on 20 patients, collecting clinical and trichoscopic images at the Dermatology Unit of the University of Bologna, Italy.</p><p><strong>Results: </strong>Scalp lesions exhibited distinct morphological characteristics in both vascular and desquamation patterns. Three main trichoscopic patterns with a different grade of involvement were identified: erythematous pattern, erythematous desquamative pattern and exudative with crusts pattern. As for the limitations, the sample size was relatively small, and, being a single-centre study, the results may not be applicable to other populations or settings. In addition, no standardized criteria for trichoscopic analysis are available.</p><p><strong>Conclusions: </strong>This is the first study with the purpose to delineate the trichoscopic characteristics observed in patients with moderate-to-severe AD not in systemic therapy, thereby highlighting three distinct patterns of trichoscopy manifestations that define three distinct populations.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143382553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-02-03DOI: 10.23736/S2784-8671.24.08123-4
Federica Filippi, Francesco P Salamone, Alice N Rossi, Lidia Sacchelli, Bianca M Piraccini, Federico Bardazzi
{"title":"A case of trigeminal trophic syndrome.","authors":"Federica Filippi, Francesco P Salamone, Alice N Rossi, Lidia Sacchelli, Bianca M Piraccini, Federico Bardazzi","doi":"10.23736/S2784-8671.24.08123-4","DOIUrl":"https://doi.org/10.23736/S2784-8671.24.08123-4","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143079990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30DOI: 10.23736/S2784-8671.24.07996-9
Fan Lin, Tsen-Fang Tsai
Risankizumab (Skyrizi®, Abbvie, North Chicago, IL, USA) is a humanized immunoglobulin (Ig) G1 monoclonal antibody targeting the p19 subunit of IL-23, thereby inhibiting IL-23-dependent releasing of proinflammatory cytokines in plaque psoriasis. Risankizumab is licensed is most countries for the treatment of patients with moderate-to-severe plaque psoriasis, and in Japan for generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis. Risankizumab showed higher efficacy and favorable safety profiles in patients with moderate-to-severe plaque psoriasis, compared with adalimumab, secukinumab and ustekinumab in several randomized controlled phase 3 pivotal studies and among real-life data in large retrospective studies. Furthermore, its high efficacy even in patients with prior biologic failure, better drug survival, less need for biologic switch and longer drug-free remission durations have also been shown in real-life settings and in long-term follow up. In addition, reports of both reduced dosing and increased (bolus) dosing exist which increase our ability to use risankizumab more flexibly in an era of personalized medicine. Also, the use of risankizumab in several special population, such as elderly, Asian people, erythrodermic psoriasis, patients with high induction doses, pregnancy and human immunodeficiency virus group are discussed.
{"title":"Efficacy and safety of risankizumab for the treatment of patients with plaque type psoriasis.","authors":"Fan Lin, Tsen-Fang Tsai","doi":"10.23736/S2784-8671.24.07996-9","DOIUrl":"https://doi.org/10.23736/S2784-8671.24.07996-9","url":null,"abstract":"<p><p>Risankizumab (Skyrizi<sup>®</sup>, Abbvie, North Chicago, IL, USA) is a humanized immunoglobulin (Ig) G1 monoclonal antibody targeting the p19 subunit of IL-23, thereby inhibiting IL-23-dependent releasing of proinflammatory cytokines in plaque psoriasis. Risankizumab is licensed is most countries for the treatment of patients with moderate-to-severe plaque psoriasis, and in Japan for generalized pustular psoriasis, erythrodermic psoriasis and palmoplantar pustulosis. Risankizumab showed higher efficacy and favorable safety profiles in patients with moderate-to-severe plaque psoriasis, compared with adalimumab, secukinumab and ustekinumab in several randomized controlled phase 3 pivotal studies and among real-life data in large retrospective studies. Furthermore, its high efficacy even in patients with prior biologic failure, better drug survival, less need for biologic switch and longer drug-free remission durations have also been shown in real-life settings and in long-term follow up. In addition, reports of both reduced dosing and increased (bolus) dosing exist which increase our ability to use risankizumab more flexibly in an era of personalized medicine. Also, the use of risankizumab in several special population, such as elderly, Asian people, erythrodermic psoriasis, patients with high induction doses, pregnancy and human immunodeficiency virus group are discussed.</p>","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-30DOI: 10.23736/S2784-8671.24.08007-1
Jacqueline Kussini, Dario Didona, Erhard Bierhoff, Ursula Steinert, Markus Steinert
{"title":"Sitosterolemia: a new ABCG5 mutation.","authors":"Jacqueline Kussini, Dario Didona, Erhard Bierhoff, Ursula Steinert, Markus Steinert","doi":"10.23736/S2784-8671.24.08007-1","DOIUrl":"https://doi.org/10.23736/S2784-8671.24.08007-1","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-01-27DOI: 10.23736/S2784-8671.25.08035-1
Edoardo Mortato, Giorgia Sbarra, Riccardo Viola, Alexandre R Meduri, Felice Primavera, Francesco Loconsole
{"title":"Efficacy and safety of treatment with biological drugs in psoriasis patients with a history of malignancies: a single-center observational study.","authors":"Edoardo Mortato, Giorgia Sbarra, Riccardo Viola, Alexandre R Meduri, Felice Primavera, Francesco Loconsole","doi":"10.23736/S2784-8671.25.08035-1","DOIUrl":"https://doi.org/10.23736/S2784-8671.25.08035-1","url":null,"abstract":"","PeriodicalId":14526,"journal":{"name":"Italian Journal of Dermatology and Venereology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143046519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号